IP Library Granted Patent US 12703854
Granted Patent B2
US 12703854 · App. 17/408,740 · Granted Aug 11, 2026

In vitro method of differentiating a human pluripotent stem cell population into a cardiomyocyte cell population

Inventors: Stefan Robbert Braam (Leiden, NL); Ana Catarina Martins Grandela (Leiden, NL)
Assignee: NCARDIA B.V.
C12N5/0657C12N2500/25C12N2501/105C12N2501/415C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12703854
App. No.
17/408,740
Granted
Aug 11, 2026
Kind
B2
Abstract

The current invention relates to a method of differentiation of human pluripotent stem cells into a human stem-cell derived population of cardiomyocytes. The method comprises the use of specific combination of steps and compounds to induce and/or promote differentiation. The method also comprises steps directed to further maturation of the cardiomyocytes obtained with the method of the invention. Also provided are kits for use in a method of differentiation as well as cell populations obtainable with the method disclosed.

Claims (3)

1 . A composition comprising a pluripotent stem cell (PSC) population in an aqueous media with a first compound that stimulates betacatenin degradation and a second compound that suppresses phosphorylation of dishevelled 2 , wherein the first compound is a tankyrase inhibitor that comprises XAV-939 and the second compound is a porcupine inhibitor that comprises IWP-L6, and wherein the XAV-939 is in a concentration of from 1 μM to about 10 μM and the IWP-L6 is in a concentration of from 0.25 μM to about 2 μM.

2 . The composition of claim 1 , wherein the composition is effective to produce a cardiomyocyte cell population in which at least 80% of the cells express the ventricular cardiomyocyte marker mlc2v.

3 . The composition of claim 1 , wherein the composition is effective to produce a cardiomyocyte cell population in which at least 70% of the cells express the ventricular cardiomyocyte marker mlc2v.